BioNTech SE (NASDAQ:BNTX) Given Average Rating of “Moderate Buy” by Analysts

Shares of BioNTech SE (NASDAQ:BNTX) have received an average rating of “Moderate Buy” from the seventeen analysts that are covering the company, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold recommendation, twelve have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $140.76.

A number of research analysts recently issued reports on the stock. HSBC raised their price objective on shares of BioNTech from $97.00 to $136.00 and gave the company a “buy” rating in a report on Monday, October 7th. JPMorgan Chase & Co. cut their price target on shares of BioNTech from $124.00 to $122.00 and set a “neutral” rating on the stock in a report on Tuesday, November 26th. Canaccord Genuity Group increased their price objective on BioNTech from $171.00 to $171.44 and gave the company a “buy” rating in a report on Wednesday, November 27th. The Goldman Sachs Group raised BioNTech from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $90.00 to $137.00 in a report on Friday, November 8th. Finally, Jefferies Financial Group raised BioNTech from a “hold” rating to a “buy” rating and increased their price target for the company from $96.00 to $150.00 in a research note on Tuesday, September 17th.

Institutional Investors Weigh In On BioNTech

Hedge funds and other institutional investors have recently bought and sold shares of the stock. GAMMA Investing LLC boosted its position in shares of BioNTech by 21.7% during the 3rd quarter. GAMMA Investing LLC now owns 623 shares of the company’s stock worth $74,000 after purchasing an additional 111 shares in the last quarter. Blue Trust Inc. grew its stake in BioNTech by 491.1% in the third quarter. Blue Trust Inc. now owns 467 shares of the company’s stock valued at $55,000 after acquiring an additional 388 shares during the period. Gallacher Capital Management LLC grew its stake in BioNTech by 12.1% in the second quarter. Gallacher Capital Management LLC now owns 3,657 shares of the company’s stock valued at $294,000 after acquiring an additional 395 shares during the period. TD Asset Management Inc increased its holdings in shares of BioNTech by 6.1% during the second quarter. TD Asset Management Inc now owns 7,590 shares of the company’s stock valued at $612,000 after acquiring an additional 435 shares in the last quarter. Finally, Planning Capital Management Corp raised its position in shares of BioNTech by 45,000.0% during the third quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock worth $54,000 after purchasing an additional 450 shares during the period. 15.52% of the stock is owned by institutional investors.

BioNTech Stock Performance

NASDAQ BNTX opened at $113.95 on Friday. BioNTech has a fifty-two week low of $76.53 and a fifty-two week high of $131.49. The stock has a market cap of $27.32 billion, a PE ratio of -54.26 and a beta of 0.22. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. The firm’s fifty day moving average price is $113.01 and its two-hundred day moving average price is $101.36.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.26) by $2.07. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business had revenue of $1.24 billion for the quarter, compared to analyst estimates of $514.08 million. During the same quarter in the previous year, the company posted $0.73 EPS. BioNTech’s quarterly revenue was up 38.9% compared to the same quarter last year. On average, equities analysts expect that BioNTech will post -3.72 EPS for the current fiscal year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.